| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 27, 2007
From the Agnes Ginges Centre for Molecular Cardiology (T.T., M.K., J.-E.T., E.T., L.L., C.S.), Centenary Institute, Sydney, New South Wales, Australia; Central Clinical School (T.T., C.S.), University of Sydney, New South Wales, Australia; Department of Biochemistry and Molecular Biology (D.C.H.N., M.B.), Bio21 Institute, University of Melbourne, Victoria, Australia; Department of Genetics and Howard Hughes Medical Institute (C.E.S., J.G.S.), Harvard Medical School, Boston, Mass; Cardiovascular Division (C.E.S.), Brigham and Women's Hospital, Boston, Mass; and Department of Cardiology (C.S.), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. * To whom correspondence should be addressed. E-mail: c.semsarian{at}centenary.org.au.
Background—Familial hypertrophic cardiomyopathy (FHC) is characterized by genetic and clinical heterogeneity. Five percent of FHC families have 2 FHC-causing mutations, which results in earlier disease onset, increased cardiac dysfunction, and a higher incidence of sudden death events. These observations suggest a relationship between the number of gene mutations and phenotype severity in FHC. Methods and Results—We sought to develop, characterize, and investigate the pathogenic mechanisms in a double-mutant murine model of FHC. This model (designated TnI-203/MHC-403) was generated by crossbreeding mice with the Gly203Ser cardiac troponin I (TnI-203) and Arg403Gln Conclusions—TnI-203/MHC-403 double-mutant mice develop a severe cardiac phenotype characterized by heart failure and early death. The presence of 2 disease-causing mutations may predispose individuals to a greater risk of developing severe heart failure than human FHC caused by a single gene mutation.
Accepted on January 16, 2008
Severe Heart Failure and Early Mortality in a Double-Mutation Mouse Model of Familial Hypertrophic Cardiomyopathy
Tatiana Tsoutsman PhD,
-myosin heavy chain (MHC-403) FHC-causing mutations. The mortality rate in TnI-203/MHC-403 mice was 100% by age 21 days. At age 14 days, TnI-203/MHC-403 mice developed a significantly increased ratio of heart weight to body weight, marked interstitial myocardial fibrosis, and increased expression of atrial natriuretic factor and brain natriuretic peptide compared with nontransgenic, TnI-203, and MHC-403 littermates. By age 16 to 18 days, TnI-203/MHC-403 mice rapidly developed a severe dilated cardiomyopathy and heart failure, with inducibility of ventricular arrhythmias, which led to death by 21 days. Downregulation of mRNA levels of key regulators of Ca2+ homeostasis in TnI-203/MHC-403 mice was observed. Increased levels of phosphorylated STAT3 were observed in TnI-203/MHC-403 mice and corresponded with the onset of disease, which suggests a possible cardioprotective response.
Related Article:
Circulation 2008 117: 1769.
This article has been cited by other articles:
![]() |
D. Hilfiker-Kleiner and R. Knoll Disease-Modifying Mutations in Familial Hypertrophic Cardiomyopathy: Complexity From Simplicity Circulation, April 8, 2008; 117(14): 1775 - 1777. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |